Difference in mode of action of cimetidine and gefarnate on endogenous prostacyclin, prostaglandin E2 and thromboxane in rat gastric mucosa.
The effects of cimetidine and gefarnate on endogenous prostacyclin, prostaglandin E2 and thromboxane were studied in vivo in rat gastric mucosa. The animals received cimetidine (20 mg/kg, i.p.) and/or gefarnate (100 mg/kg, s.c.) twice a day for 7 days. Gastric mucosal 6-keto-prostaglandin F1 alpha (as prostacyclin), prostaglandin E2 and thromboxane B2 (as thromboxane A2) were determined by radioimmunoassay. Cimetidine reduced prostacyclin, prostaglandin E2, but not thromboxane A2. Gefarnate inhibited the cimetidine-induced reduction of prostacyclin and prostaglandin E2; in cimetidine-untreated controls, it did not produce an increase in those prostaglandins and thromboxane A2 above the normal levels.
D000818:Animals; D002927:Cimetidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003864:Depression, Chemical; D015232:Dinoprostone; D011464:Epoprostenol / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D005778:Gefarnate / Q000494:pharmacology*; D008297:Male; D011458:Prostaglandins E / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D013729:Terpenes / Q000494:pharmacology*; D013931:Thromboxanes / Q000378:metabolism*
D011458:Prostaglandins E; D013729:Terpenes; D013931:Thromboxanes; D005778:Gefarnate; D002927:Cimetidine; D011464:Epoprostenol; D015232:Dinoprostone